WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574299

CAS#: 832-68-8

Description: 6-Aminophenanthridine is an antiprion agent. It inhibits prion formation in yeast- and mammalian-based screening assays when used alone and, to a greater extent, when used in combination with the α2-adrenergic receptor agonist guanabenz. 6-Aminophenanthridine inhibits protein folding activity of the ribosome (PFAR) by directly competing with protein substrates for the active site and decreases the yield of refolded protein without affecting the refolding rate. It prevents progressive wing position defects in a Drosophila model of oculopharyngeal muscular dystrophy (OPMD) when larvae are raised on medium containing doses ranging from 300 to 400 µM and in adults following dietary administration of 1-3 mM doses. 6-Aminophenanthridine also reduces muscle degeneration and decreases the number of nuclear inclusions in thoracic muscle in a Drosophila model of OPMD.

Chemical Structure

CAS# 832-68-8

Theoretical Analysis

MedKoo Cat#: 574299
Name: 6-Aminophenanthridine
CAS#: 832-68-8
Chemical Formula: C13H10N2
Exact Mass: 194.0844
Molecular Weight: 194.24
Elemental Analysis: C, 80.39; H, 5.19; N, 14.42

Price and Availability

Size Price Availability Quantity
1.0mg USD 205.0 2 Weeks
5.0mg USD 380.0 2 Weeks
10.0mg USD 615.0 2 Weeks
25.0mg USD 1150.0 2 Weeks
Bulk inquiry

Synonym: 6-Aminophenanthridine, 6AP

IUPAC/Chemical Name: 6-phenanthridinamine


InChi Code: InChI=1S/C13H10N2/c14-13-11-7-2-1-5-9(11)10-6-3-4-8-12(10)15-13/h1-8H,(H2,14,15)

SMILES Code: NC1=C(C=CC=C2)C2=C(C=CC=C3)C3=N1

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 194.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Tribouillard-Tanvier, D., Dos Reis, S., Gug, F., et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 3(5), e2174 (2008).

2. Pang, Y., Kurella, S., Voisset, C., et al. The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. J. Biol. Chem. 288(26), 19081-19089 (2013).

3. Banerjee, D., Vovusha, H., Pang, Y., et al. Spectroscopic and DFT studies on 6-Aminophenanthridine and its derivatives provide insights in their activity towards ribosomal RNA. Biochimie 97, 194-199 (2014).

4. Barbezier, N., Chartier, A., Bidet, Y., et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol. Med. 3(1), 35-49 (2011).